Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Nov 12 - Nov 17
The DXN group was administered an intraperitoneal dose of 5 mg/kg body weight (BW) for four cycles (cumulative dose 20 mg/kg), with each cycle separated by a three-day interval, and this dosage was consistent with the therapeutic levels typically administered to individuals receiving cancer treatment ( 2.4 Mortality rate and body weight The daily routine monitoring of mortality rates provided vital insights for the ongoing research
It is hypothesized that augmentation therapy could improve inflammation, reduce bronchial hyperresponsiveness, and prevent the development of chronic airway changes in these patients
in group 1, there was subtle decrease in density of
Genetics 135 , 489505 (1993)
US$ 20.21
US$ 27.82
US$ 20.59
